New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 21, 2014
06:33 EDTCYTRCytRx receives FDA approval to continue aldoxorubicin clinical trial
CytRx announced it has received approval from the FDA to continue dosing patients with aldoxorubicin until disease progression in a planned pivotal, global Phase 3 clinical trial with aldoxorubicin as a second-line treatment for soft tissue sarcomas. The clinical trial is scheduled to begin this quarter. For purposes of the clinical trial, disease progression is defined as an increase in the size of measurable tumors by 20% or the development of a new tumor lesion.
News For CYTR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
06:14 EDTCYTRCytRx annouces publication of preclinical glioblastoma data in Neoplasia
Subscribe for More Information
October 20, 2014
06:09 EDTCYTRCytRx announces positive data from Phase 1b/2 study of Aldoxorubicin
Subscribe for More Information
October 17, 2014
09:17 EDTCYTROn The Fly: Pre-market Movers
Subscribe for More Information
06:15 EDTCYTRCytRx aldoxorubicin trial not yet reached enough survival events to report OS
CytRx announced that data regarding the company's Phase 2b global clinical trial of aldoxorubicin for the treatment of first-line soft tissue sarcoma, or STS, will be presented in a moderated paper presentation at the 2014 Connective Tissue Oncology Society Annual Meeting which is being held October 15-18, 2014, in Berlin, Germany. Due to the longer than expected survival of patients in the clinical trial, there have not been a sufficient number of survival events to enable the company to report data on overall survival, or OS, a secondary endpoint of the study.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use